Clearside Biomedical announces six presentations related to CLS-AX

Clearside Biomedical (CLSD) announced that six presentations related to the Company’s lead program, CLS-AX, and suprachoroidal drug delivery platform were featured at the Association for Research in Vision and Ophthalmology, ARVO, 2025 Meeting. Presentation Key Highlights: Positive data presented from the CLS-AX Phase 2b ODYSSEY trial, which achieved the primary outcome of maintaining stable best corrected visual acuity with repeat dosing while meaningfully reducing the frequency of injections.Clearside’s Phase 3 trial design to feature the flexible dosing of an anti-VEGF biologic with the duration of a pan-VEGF receptor tyrosine kinase inhibitor. Poster featuring data on CLS-AX, XIPERE, and viral and non-viral gene therapy data showed that suprachoroidal drug and gene therapy delivery with Clearside’s SCS Microinjector holds a promising future for treating chorioretinal diseases. Clearside has developed a novel force analysis method designed to provide real-time, formulation-specific feedback that goes beyond ISO compliance, evaluate the injectability of suspensions and allow for better drug-device co-optimization. Clearside leverages these test methods to design internal drug candidate formulations and assist partners with designs specifically for suprachoroidal injection using the SCS Microinjector.